Veru is trading 5.14% higher at $2.76, with no clear company-specific catalyst identified for August 31, 2026.
- Latest notable updates include the August 10 fiscal third-quarter report, full enrollment in the 239-patient PLATEAU trial, and potential patent protection through 2044.
- These developments are several weeks old and do not directly explain today’s move.
- Broader markets are lower, and the gain is not clearly tied to overall sentiment; confidence remains low.